Hydroxychloroquine for COVID-19 PEP

01 Jun Hydroxychloroquine for COVID-19 PEP

Post-exposure prophylaxis (PEP) is defined as taking antimicrobial medication after being exposed or potentially exposed to an infectious agent to prevent becoming infected. PEP is routinely used for prevention of a variety of viral, bacterial, and parasitic infections, including influenza and human immunodeficiency virus (HIV).

This is a randomized, multi-center, placebo-equivalent (ascorbic acid) controlled, blinded study of hydroxychloroquine (HCQ) PEP for the prevention of COVID-19 infection in adults exposed to the coronavirus. This study will enroll up to 2,000 men and women who meet the eligibility criteria from multiple sites in the United States.

Volunteers who participate in the study will be asked to take a medication (either HCQ or vitamin C), complete an online survey to assess their symptoms, and collect a sample by swabbing the inside of their nose every day for 14 days. On Day 28 a final swab will be collected and a survey completed. Volunteers will be in the study for approximately 28 days.
________________________________________________________________________________________________

**If you are interested in participating, please visit: https://depts.washington.edu/covid19pep/
Directly click on the link on the right marked “Contact for More Information” and complete the pre-screening form.**

Participant Eligibility

– Men or women 18 to 80 years of age inclusive, at the time of signing the informed consent
– Had close contact* of a person (index) with known PCR-confirmed SARS-CoV-2 infection or index who is currently being assessed for COVID-19
*Close contact is defined as:
a. Household contact
b. Medical staff, first responders, or other care persons who cared for the index case without personal protection (mask and gloves)
– Less than 4 days since last exposure (close contact with a person with SARS-CoV-2 infection)
– Access to device and internet for Telehealth visits

Contact

UW COVID-19 PEP team
(206) 520-4366

Additional Study Details

Full Study Title
Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): A Blinded, Randomized Study

Investigator(s)
Dr. Ruanne V. Barnabas, University of Washington
Dr. Anna Bershteyn, NYU School of Medicine

Accepts Healthy Volunteers?
Yes

Study Site(s)